Table 4 Characteristics of mTORi administration in the included cases (n = 48).
From: Everolimus and sirolimus in the treatment of cardiac rhabdomyomas in neonates
Authors/ Year of Publication | Age at the Start of Tx (days) | Medication | Approx. Accumulated Dose mg/m2/week | Approx. Accumulated Dose mg/kg/week | mTORi Target Serum Level ng/mL | Max. Serum Level mTORi ng/mL | Initial dose changes | Duration of Tx (days) | AE | Tx Suspension Due to AE | Rebound | Final Mass Reduction (%) | Total Follow-up Time (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Demir et al.38 | – | Everolimus | – | 0.59 | 5 a 15 | 83.5 (day 7) | Yes | 70 | Yes | Yes | Yes | – | – |
Breathnach et al. 39 | 10 | Sirolimus | – | – | 20 | 26 (day 7) | Yes | 24 | No | No | Yes | 66 | 7.92 |
Goyer et al.40 | 20 | Everolimus | – | 0.71 | 5 a 15 | 13.7 (day 4) | No | 34 | No | Yes | No | – | 10.68 |
Goyer et al.40 | 4 | Everolimus | – | 0.42 | 5 a 15 | 11.5 (day 15) | No | 77 | Yes | No | Yes | 55.9 | 8.76 |
Wagner et al. 41 | 2 | Everolimus | 12.25 | 1.02 | 5 a 15 | 108 (day 4) | Yes | 19 | Yes | No | No | 24.3 | 5.04 |
Aw et al. 201612 | 20 | Everolimus | 7 | 0.71 | 5 a 15 | 13.7 (day 4) | No | 34 | No | Yes | Yes | 21 | |
Aw et al. 201612 | 4 | Everolimus | 5 | 0.42 | 5 a 15 | 11 (day 6) | No | 46 | No | No | Yes | 50 | 21 |
Aw et al. 201612 | 1 | Everolimus | 3.3 | 0.21 | 5 a 15 | 10.2 (day 10) | No | 36 | No | No | Yes | 50 | 18.84 |
Colaneri et al.42 | 7 | Everolimus | 10.5 | 0.77 | 5 a 15 | 16 (day 40) | Yes | 70 | No | No | No | 80 | 9 |
Chang et al.43 | 7 | Everolimus | 2.17 | 0.14 | 3 a 7 | 5.59 (day 35) | Yes | 187 | Yes | No | Yes | – | – |
Chang et al.43 | 5 | Everolimus | 2.31 | 0.15 | 3 a 7 | 20 (day 50) | Yes | 94 | No | Yes | Yes | 86.7 | 23.04 |
Chang et al.43 | 2 | Everolimus | 4.55 | 0.32 | 3 a 7 | 16 (day 5) | Yes | 90 | No | Yes | Yes | 80.5 | 9.96 |
Lee at al. 44 | 18 | Sirolimus | 15.9 | 1.46 | 10 a 20 | 42.1 (day 14) | Yes | 57 | No | No | No | 55.7 | 9.6 |
Schmidt-Fittschen et al.45 | 11 | Everolimus | – | 0.33 | 6 a 10 | – | No | 319 | Yes | No | Yes | 77.1 | 24 |
Martínez-García et al.46 | 36 | Everolimus | – | 0.33 | – | – | No | 64 | No | No | No | – | 3.96 |
Weiland et al. 47 | – | Sirolimus | – | 0.7 | 5 a 15 | – | No | 30 | No | No | Yes | 86 | 9.96 |
Weiland et al. 47 | – | Sirolimus | – | 1.4 | 5 a 15 | 24.3 (day 12) | Yes | – | No | – | No | 43.4 | – |
Dhulipudi et al.48 | 3 | Everolimus | 4.5 | – | – | – | No | 112 | No | No | – | 14.3 | – |
Dhulipudi et al.48 | 1 | Everolimus | 4.5 | – | – | – | No | 56 | Yes | No | – | 27.7 | – |
Dhulipudi et al.48 | 90 | Everolimus | 4.5 | – | – | – | No | 56 | Yes | No | Yes | 50 | – |
Dhulipudi et al.48 | 7 | Everolimus | 4.5 | – | – | – | Yes | 42 | No | Yes | Yes | 50 | – |
Dhulipudi et al.48 | 6 | Everolimus | 4.5 | – | – | – | No | 224 | No | No | No | 38.5 | – |
Garg et al. 201914 | 4 | Everolimus | 2.1 | – | – | – | Yes | – | Yes | – | – | – | 6 |
Lawley et al.49 | 3 | Sirolimus | 10.93 | 0.79 | 5 a 15 | 69.7 (day 8) | Yes | 60 | No | Yes | Yes | – | 12 |
Shibata et al.50 | 4 | Everolimus | 19.6 | 1.38 | 5 a 15 | 76.1 (day 3) | Yes | 6 | No | Yes | No | 31.4 | 1.8 |
Esmer - Sánchez et al.51 | 4 | Everolimus | 31.5 | – | 5 a 10 | 26.8 (day 14) | Yes | 730 | Yes | No | No | 73.3 | 24 |
Prasad et al.52 | 2 | Everolimus | 4.5 | – | – | – | No | 112 | Yes | – | – | – | 2.4 |
Çetin et al. 53 | 90 | Everolimus | 4.5 | – | – | – | No | 120 | No | No | No | 65.8 | – |
Nespoli et al.7 | 26 | Everolimus | – | 0.15 | 3 a 8 | 4.5 (day 5) | No | 180 | No | – | No | 50 | – |
Nir-David et al. 54 | 120 | Sirolimus | 8 | 0.42 | 5 a 15 | 16.67 (day 6) | Yes | 30 | No | – | Yes | 63 | – |
Relan et al.55 | 2 | Sirolimus | 10.5 | 0.7 | 10 a 15 | 27.1 (day 24) | Yes | 344 | No | No | Yes | 90 | 37.2 |
Silva-Sánchez et al. 56 | 3 | Everolimus | – | 0.7 | 5 a 8 | – | No | 42 | No | – | No | 45.2 | 12 |
Tsuchihashi et al. 57 | 28 | Everolimus | 4.9 | 0.52 | 5 a 15 | 14.3 (day 14) | No | 180 | No | – | – | 73 | 6 |
Beyazal et al.58 | – | Everolimus | 4.55 | – | 5 a 15 | 8 (day 8) | No | 119 | No | – | No | 100 | 3 |
Çetiner et al. 59 | 7 | Everolimus | 0.6 | – | – | – | Yes | – | Yes | – | – | 86.1 | 24 |
Inoue et al.60 | 7 | Everolimus | 14 | – | 5 a 15 | 67 (day 7) | Yes | – | No | Yes | – | 28 | – |
Sagiv et al. 61 | 8 | Everolimus | – | 0.23 | 5 a 10 | 11,4 | No | 35 | Yes | Yes | Yes | 75 | 4.92 |
Winkie et al.62 | – | Sirolimus | 4.2 | – | 5 a 15 | – | No | – | Yes | – | – | 70.8 | 10.92 |
Babaoğlu et al.63 | 2 | Everolimus | – | 1.47 | 5 a 15 | 37.1 | No | 25 | Yes | No | – | 3 | – |
Babaoğlu et al.63 | 4 | Everolimus | – | 0.31 | 5 a 15 | 9.3 | No | 70 | Yes | – | – | 64 | 36 |
Babaoğlu et al.63 | 3 | Everolimus | – | 0.33 | 5 a 15 | 11.3 | Yes | 70 | Yes | Yes | No | 46 | 6.96 |
Babaoğlu et al.63 | 105 | Everolimus | – | 0.12 | 5 a 15 | 12.6 | Yes | 56 | No | Yes | Yes | 66 | 6 |
Babaoğlu et al.63 | 6 | Everolimus | – | 0.24 | 5 a 15 | 7.6 | No | 84 | No | – | – | 42 | 24.96 |
Babaoğlu et al.63 | 8 | Everolimus | – | 0.34 | 5 a 15 | 8.9 | No | 42 | No | – | – | 36 | 9.96 |
Babaoğlu et al.63 | 6 | Everolimus | – | 0.35 | 5 a 15 | 8.5 | No | 35 | – | – | – | 48 | 6 |
Hurtado-Sierra D et al. 64 | 2 | Everolimus | 4.4 | 0.31 | 5 a 15 | 8.4 (day 6) | No | 84 | Yes | No | Yes | 79.1 | 22.8 |
Hurtado-Sierra D et al. 64 | 3 | Everolimus | 3.9 | 0.24 | 5 a 15 | 11,5 (day 7) | No | 121 | Yes | No | Yes | 78.6 | 15.6 |
Montaguti et al. 65 | 60 | Everolimus | 2.4 | 0.14 | 3 a 8 | 2.4 (day 15) | No | – | No | – | – | 30.9 | 6 |
